Updates on the Role of FDG-PET/CT in Gynecological Malignancies

Abstract

PET/CT has had an evolutionary role in Oncology. Gynecological malignancies have been increasing in incidence in the last decades. Delay in diagnosis and management have led to worsening prognosis among the patients. Lowering the threshold in suspecting these tumors, may significantly improve the patients’ overall survival. In this review we will address the role of FDG-PET/CT in diagnosing, staging, assessing the response to therapy and predicting survival in gynecological malignancies, namely endometrial, ovarian and cervical cancer. We will briefly compare the diagnosing ability of PET/MRI to PET/CT. We will address the interesting fact about simultaneously utilizing the Apparent Diffusion Coefficient (ADC) with the Standardized Uptake Value (SUV) in hybrid MRI imaging and we will also discuss about the role of PET/MRI in diagnosing primary and recurrent gynecological malignancies.